In the ODYSSEY open-label extension study, spanning an average observation period of 2.5 years, no significant increase in sudden adverse events was observed in patients with familial hypercholesterolemia undergoing PCSK9 monoclonal antibody treatment (Farnier et al., 2018). The gene discussed is PCSK9; the disease is familial hypercholesterolemia.